Use of cannabidiol (CBD) for the treatment of chronic pain
Copyright © 2020. Published by Elsevier Ltd..
Chronic pain can be recurrent or constant pain that lasts for longer than 3 months and can result in disability, suffering, and a physical disturbance. Related to the complex nature of chronic pain, treatments have a pharmacological and non-pharmacological approach. Due to the opioid epidemic, alternative therapies have been introduced, and components of the plant Cannabis Sativa, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained recent interest as a choice of treatment. The exact mechanism for CBD is currently unknown, but unlike the CBD's psychoactive counterpart, THC, the side effects of CBD itself have been shown to be overall much more benign. The current pharmaceutical products for the treatment of chronic pain are known as nabiximols, and they contain a ratio of THC combined with CBD, which has been promising. This review focuses on the treatment efficacy of CBD, THC: CBD-based treatments for chronic pain and adverse events with each.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical anaesthesiology - 34(2020), 3 vom: 06. Sept., Seite 463-477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Urits, Ivan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19GBJ60SN5 |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bpa.2020.06.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315745649 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315745649 | ||
| 003 | DE-627 | ||
| 005 | 20231225155600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpa.2020.06.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315745649 | ||
| 035 | |a (NLM)33004159 | ||
| 035 | |a (PII)S1521-6896(20)30045-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of cannabidiol (CBD) for the treatment of chronic pain |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 01.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
| 520 | |a Chronic pain can be recurrent or constant pain that lasts for longer than 3 months and can result in disability, suffering, and a physical disturbance. Related to the complex nature of chronic pain, treatments have a pharmacological and non-pharmacological approach. Due to the opioid epidemic, alternative therapies have been introduced, and components of the plant Cannabis Sativa, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained recent interest as a choice of treatment. The exact mechanism for CBD is currently unknown, but unlike the CBD's psychoactive counterpart, THC, the side effects of CBD itself have been shown to be overall much more benign. The current pharmaceutical products for the treatment of chronic pain are known as nabiximols, and they contain a ratio of THC combined with CBD, which has been promising. This review focuses on the treatment efficacy of CBD, THC: CBD-based treatments for chronic pain and adverse events with each | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cannabidiol | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a nabiximols | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Cannabinoid Receptor Agonists |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Cannabidiol |2 NLM | |
| 650 | 7 | |a 19GBJ60SN5 |2 NLM | |
| 650 | 7 | |a Dronabinol |2 NLM | |
| 650 | 7 | |a 7J8897W37S |2 NLM | |
| 650 | 7 | |a nabiximols |2 NLM | |
| 650 | 7 | |a K4H93P747O |2 NLM | |
| 700 | 1 | |a Gress, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Charipova, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Habib, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jai Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kassem, Hisham |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse |e verfasserin |4 aut | |
| 700 | 1 | |a Paladini, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Varrassi, Giustino |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical anaesthesiology |d 2002 |g 34(2020), 3 vom: 06. Sept., Seite 463-477 |w (DE-627)NLM122752538 |x 1878-1608 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:3 |g day:06 |g month:09 |g pages:463-477 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bpa.2020.06.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 3 |b 06 |c 09 |h 463-477 | ||